Dynavax Technologies | DVAX - Cash And Equivalent


Dynavax Technologies reported $160.25M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.63B 838M Sep/2025
Adma Biologics USD 61.38M 28.9M Sep/2025
Amgen USD 9.13B 316M Dec/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
Biogen USD 3.86B 1.1B Sep/2025
BioMarin Pharmaceutical USD 1.25B 36.29M Sep/2025
Bristol-Myers Squibb USD 15.73B 3.13B Sep/2025
Dynavax Technologies USD 160.25M 61.15M Sep/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
Glaxosmithkline GBP 3.3B 303M Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Neurocrine Biosciences USD 340.2M 76.2M Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sarepta Therapeutics USD 613.08M 102.48M Sep/2025
TG Therapeutics USD 178.32M 100.54M Sep/2025
Vertex Pharmaceuticals USD 6.29B 95.8M Sep/2025